BioCentury
ARTICLE | Clinical News

Sun's IL-23 psoriasis mab approved by FDA

March 23, 2018 6:29 PM UTC

Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA) said FDA approved Ilumya tildrakizumab-asmn (MK-3222) to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Ilumya is a humanized mAb against IL-23 subunit alpha (IL23P19; IL-23A). Sun has worldwide, ex-European rights to the drug from Merck & Co. Inc. (NYSE:MRK)...